Vapotherm's 3Q22 result continues to reinforce the material headwinds being experienced by F&P Healthcare's (FPH) Hospital segment, particularly consumables utilisation and highlights further downside risk to consensus expectations
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.